The Japanese experience with biologic therapies for rheumatoid arthritis

Tsutomu Takeuchi, Hideto Kameda

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The unique genetic, environmental and medical backgrounds of people in Japan might influence the effectiveness and safety of biologic agents in patients with rheumatoid arthritis (RA). Indeed, clinical trials revealed higher response rates to some biologic agents (including infliximab, etanercept and tocilizumab) in patients with RA in Japan than patients treated with the same agents in Western countries, although response rates to adalimumab were comparable in both populations. The reasons why response rates to some biologic agents differ in Japanese individuals is currently under investigation. Post-marketing surveillance data have been collected for all patients with RA who were treated with biologic agents in Japan to monitor drug safety. These data clearly demonstrated that only ∼5% of these patients experienced adverse drug reactions to biologic agents, which were well tolerated. Pneumonia, tuberculosis, Pneumocystis jirovecii pneumonia and interstitial pneumonitis are considered important severe adverse reactions and risk factors for these adverse effects have been identified. Adverse drug reactions could exaggerate the risks associated with biologic therapy in Japanese patients with RA. Attempts have, therefore, been made to predict clinical response and adverse effects to enable personalized therapy with biologic agents and to optimize the outcomes of these patients.

Original languageEnglish
Pages (from-to)644-652
Number of pages9
JournalNature Reviews Rheumatology
Volume6
Issue number11
DOIs
Publication statusPublished - 2010 Nov

Fingerprint

Biological Therapy
Biological Factors
Rheumatoid Arthritis
Japan
Drug-Related Side Effects and Adverse Reactions
Safety
Pneumocystis carinii
Pneumocystis Pneumonia
Interstitial Lung Diseases
Medical Genetics
Marketing
Pneumonia
Tuberculosis
Clinical Trials
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Rheumatology

Cite this

The Japanese experience with biologic therapies for rheumatoid arthritis. / Takeuchi, Tsutomu; Kameda, Hideto.

In: Nature Reviews Rheumatology, Vol. 6, No. 11, 11.2010, p. 644-652.

Research output: Contribution to journalArticle

@article{6e67e7900f96417b954b8062707803ea,
title = "The Japanese experience with biologic therapies for rheumatoid arthritis",
abstract = "The unique genetic, environmental and medical backgrounds of people in Japan might influence the effectiveness and safety of biologic agents in patients with rheumatoid arthritis (RA). Indeed, clinical trials revealed higher response rates to some biologic agents (including infliximab, etanercept and tocilizumab) in patients with RA in Japan than patients treated with the same agents in Western countries, although response rates to adalimumab were comparable in both populations. The reasons why response rates to some biologic agents differ in Japanese individuals is currently under investigation. Post-marketing surveillance data have been collected for all patients with RA who were treated with biologic agents in Japan to monitor drug safety. These data clearly demonstrated that only ∼5{\%} of these patients experienced adverse drug reactions to biologic agents, which were well tolerated. Pneumonia, tuberculosis, Pneumocystis jirovecii pneumonia and interstitial pneumonitis are considered important severe adverse reactions and risk factors for these adverse effects have been identified. Adverse drug reactions could exaggerate the risks associated with biologic therapy in Japanese patients with RA. Attempts have, therefore, been made to predict clinical response and adverse effects to enable personalized therapy with biologic agents and to optimize the outcomes of these patients.",
author = "Tsutomu Takeuchi and Hideto Kameda",
year = "2010",
month = "11",
doi = "10.1038/nrrheum.2010.154",
language = "English",
volume = "6",
pages = "644--652",
journal = "Nature reviews. Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - The Japanese experience with biologic therapies for rheumatoid arthritis

AU - Takeuchi, Tsutomu

AU - Kameda, Hideto

PY - 2010/11

Y1 - 2010/11

N2 - The unique genetic, environmental and medical backgrounds of people in Japan might influence the effectiveness and safety of biologic agents in patients with rheumatoid arthritis (RA). Indeed, clinical trials revealed higher response rates to some biologic agents (including infliximab, etanercept and tocilizumab) in patients with RA in Japan than patients treated with the same agents in Western countries, although response rates to adalimumab were comparable in both populations. The reasons why response rates to some biologic agents differ in Japanese individuals is currently under investigation. Post-marketing surveillance data have been collected for all patients with RA who were treated with biologic agents in Japan to monitor drug safety. These data clearly demonstrated that only ∼5% of these patients experienced adverse drug reactions to biologic agents, which were well tolerated. Pneumonia, tuberculosis, Pneumocystis jirovecii pneumonia and interstitial pneumonitis are considered important severe adverse reactions and risk factors for these adverse effects have been identified. Adverse drug reactions could exaggerate the risks associated with biologic therapy in Japanese patients with RA. Attempts have, therefore, been made to predict clinical response and adverse effects to enable personalized therapy with biologic agents and to optimize the outcomes of these patients.

AB - The unique genetic, environmental and medical backgrounds of people in Japan might influence the effectiveness and safety of biologic agents in patients with rheumatoid arthritis (RA). Indeed, clinical trials revealed higher response rates to some biologic agents (including infliximab, etanercept and tocilizumab) in patients with RA in Japan than patients treated with the same agents in Western countries, although response rates to adalimumab were comparable in both populations. The reasons why response rates to some biologic agents differ in Japanese individuals is currently under investigation. Post-marketing surveillance data have been collected for all patients with RA who were treated with biologic agents in Japan to monitor drug safety. These data clearly demonstrated that only ∼5% of these patients experienced adverse drug reactions to biologic agents, which were well tolerated. Pneumonia, tuberculosis, Pneumocystis jirovecii pneumonia and interstitial pneumonitis are considered important severe adverse reactions and risk factors for these adverse effects have been identified. Adverse drug reactions could exaggerate the risks associated with biologic therapy in Japanese patients with RA. Attempts have, therefore, been made to predict clinical response and adverse effects to enable personalized therapy with biologic agents and to optimize the outcomes of these patients.

UR - http://www.scopus.com/inward/record.url?scp=78049508184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049508184&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2010.154

DO - 10.1038/nrrheum.2010.154

M3 - Article

VL - 6

SP - 644

EP - 652

JO - Nature reviews. Rheumatology

JF - Nature reviews. Rheumatology

SN - 1759-4790

IS - 11

ER -